Switch theme
Sign up to access all valuation multiples
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax’s product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company’s key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
1988
17
LTM Revenue $2.9M
Last FY EBITDA -$24.9M
$14.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Geovax Labs has a last 12-month revenue (LTM) of $2.9M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Geovax Labs achieved revenue of $4.0M and an EBITDA of -$24.9M.
Geovax Labs expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Geovax Labs valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.9M | XXX | $4.0M | XXX | XXX | XXX |
| Gross Profit | $2.9M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$24.9M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -629% | XXX | XXX | XXX |
| EBIT | -$25.4M | XXX | -$25.1M | XXX | XXX | XXX |
| EBIT Margin | -879% | XXX | -636% | XXX | XXX | XXX |
| Net Profit | -$25.3M | XXX | -$25.0M | XXX | XXX | XXX |
| Net Margin | -875% | XXX | -632% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Geovax Labs's stock price is $1.
Geovax Labs has current market cap of $15.7M, and EV of $14.3M.
See Geovax Labs trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $14.3M | $15.7M | XXX | XXX | XXX | XXX | $-3.47 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Geovax Labs has market cap of $15.7M and EV of $14.3M.
Geovax Labs's trades at 3.6x EV/Revenue multiple, and -0.6x EV/EBITDA.
Equity research analysts estimate Geovax Labs's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Geovax Labs has a P/E ratio of -0.6x.
See valuation multiples for Geovax Labs and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $15.7M | XXX | $15.7M | XXX | XXX | XXX |
| EV (current) | $14.3M | XXX | $14.3M | XXX | XXX | XXX |
| EV/Revenue | 5.0x | XXX | 3.6x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.6x | XXX | XXX | XXX |
| EV/EBIT | -0.6x | XXX | -0.6x | XXX | XXX | XXX |
| EV/Gross Profit | 5.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.6x | XXX | -0.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGeovax Labs's last 12 month revenue growth is -72%
Geovax Labs's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $1.7M for the same period.
Geovax Labs's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Geovax Labs's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Geovax Labs and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -72% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -629% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | -701% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 600% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 736% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Geovax Labs acquired XXX companies to date.
Last acquisition by Geovax Labs was XXXXXXXX, XXXXX XXXXX XXXXXX . Geovax Labs acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Geovax Labs founded? | Geovax Labs was founded in 1988. |
| Where is Geovax Labs headquartered? | Geovax Labs is headquartered in United States of America. |
| How many employees does Geovax Labs have? | As of today, Geovax Labs has 17 employees. |
| Who is the CEO of Geovax Labs? | Geovax Labs's CEO is Mr. David A. Dodd. |
| Is Geovax Labs publicy listed? | Yes, Geovax Labs is a public company listed on NAS. |
| What is the stock symbol of Geovax Labs? | Geovax Labs trades under GOVX ticker. |
| When did Geovax Labs go public? | Geovax Labs went public in 2020. |
| Who are competitors of Geovax Labs? | Similar companies to Geovax Labs include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of Geovax Labs? | Geovax Labs's current market cap is $15.7M |
| What is the current revenue of Geovax Labs? | Geovax Labs's last 12 months revenue is $2.9M. |
| What is the current revenue growth of Geovax Labs? | Geovax Labs revenue growth (NTM/LTM) is -72%. |
| What is the current EV/Revenue multiple of Geovax Labs? | Current revenue multiple of Geovax Labs is 5.0x. |
| Is Geovax Labs profitable? | Yes, Geovax Labs is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
